Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phage Therapy in S. aureus Prosthetic Joint Infection
NCT05369104Phase 2Unknown
- Sponsor
- PHAXIAM Therapeutics
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prosthetic joint infection (PJI) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Clinical control of infection at 12 weeks. Status: unknown.
02
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT05369104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369104.